A FormBlends network publication

Storage and handling of prescribed peptide medication, per label

What the Egrifta SV, Egrifta WR and Vyleesi labels say about temperature, light, reconstitution, and when to discard, side by side. For medication a prescriber prescribed and a pharmacy dispensed. With a note on why a compounded product's label, not these, governs a compounded product.

By FormBlends editorial teamUpdated September 4, 2026Educational, not medical advice

Storage-life countdown

Open full calculator

From the pharmacy label

Whatever the pharmacy label says. This tool does not need to know what it is.

Also written as BUD, 'use by' or 'discard after'. If the label gives a number of days rather than a date, ask the pharmacy for the date; do not estimate it.

Only used to show how much of the labelled window has passed.

Shown back to you as a reminder; the tool does not change the date based on it.

Countdown

Enter the beyond-use date from the pharmacy label. Today is 2026-09-04 on this device.

Two peptides on this site have FDA labels, and labels are where storage rules live. This page puts the three relevant labels side by side, exactly as written, for people who have been prescribed one of these products. It is not a guide to storing anything else, and the last section explains why.

The labels, side by side

Egrifta SV

Tesamorelin 2 mg single-dose vial, label revised 03/2024

Before mixing
20 to 25 C (68 to 77 F); excursions 15 to 30 C permitted. Keep in the original box to protect from light.
Diluent
0.5 mL of the supplied Sterile Water for Injection only. Roll gently 30 seconds; do not shake.
After mixing
Administer 0.35 mL (1.4 mg) immediately. Throw away any unused solution and diluent. Do not freeze or refrigerate the reconstituted solution.
Injection box
Sterile water, syringes and needles at 20 to 25 C.

Use only if the solution is clear, colourless and free of particles.

Egrifta WR

Tesamorelin 11.6 mg single-patient-use vial, label revised 03/2025

Before mixing
20 to 25 C (68 to 77 F) in the original box to protect from light; excursions 15 to 30 C permitted. Do not freeze.
Diluent
1.3 mL of the supplied Bacteriostatic Water for Injection (contains benzyl alcohol). Swirl; do not shake. Resulting concentration 8 mg/mL.
After mixing
Dose is 0.16 mL (1.28 mg) once daily. Discard the vial 7 days after mixing. Discard the bacteriostatic water bottle 28 days after first use.
Substitution
Egrifta WR and Egrifta SV are not substitutable (label, section 2).

Use only if the solution is clear and colourless without particles.

Vyleesi

Bremelanotide 1.75 mg in 0.3 mL prefilled single-dose autoinjector, label revised 03/2024

Storage
At or below 25 C (77 F). Do not freeze. Protect from light.
Use
One autoinjector per dose, abdomen or thigh, at least 45 minutes before anticipated activity. Dispose of the autoinjector after use.
Frequency limits
No more than one dose in 24 hours; more than 8 doses a month not recommended.
Inspect
Discard if the solution is cloudy, discoloured or contains particles.

Frequency limits are on the label because of the transient blood-pressure rise and hyperpigmentation risk; see the PT-141 page.

Reading the pattern

Three things recur across labels for injectable peptides, and they are worth understanding because they are why the rules are what they are.

Light. Peptides degrade under light. All three labels say protect from light; the Egrifta labels say to do it by leaving the vial in its box.

Preservative. Sterile water has no preservative, so a vial reconstituted with it (Egrifta SV) is a one-time solution: use it, discard the rest. Bacteriostatic water contains benzyl alcohol, which suppresses microbial growth for a limited period, so a vial reconstituted with it (Egrifta WR) can be entered repeatedly for a labelled number of days, 7 in this case. The number of days is a tested value for that formulation. It is not a general property of bacteriostatic water.

Temperature. Both Egrifta formulations are room-temperature products before reconstitution, which surprises people who assume every peptide needs a refrigerator. The label is the authority, not the assumption. The SV label goes further and says do not refrigerate the reconstituted solution.

What the Egrifta and Vyleesi labels do not cover

A compounded tesamorelin, a compounded bremelanotide, or anything sold as a research chemical. The labels describe the tested stability of specific formulations with specific excipients, fills and diluents. Change any of those and the data no longer apply. A compounding pharmacy assigns its own beyond-use date under USP General Chapter 797, based on the preparation and its sterility risk category, and prints it on the label with the storage condition. That label governs.

If a pharmacy-dispensed vial arrived without a beyond-use date or a storage instruction, that is a question for the pharmacy before use, not a gap to fill from this page. If it arrived with a number of days rather than a date, ask for the date. The pharmacy vetting checklist on our compounding site covers what a proper label shows.

The countdown

The storage-life countdown embedded above takes the beyond-use date from your pharmacy label and counts down to it, optionally showing how much of the labelled window has passed since you opened or reconstituted the vial. It performs no other calculation: it does not estimate a date from a storage rule, does not convert between conditions, and does not do reconstitution or dose arithmetic. For the arithmetic on a pharmacy-dispensed vial whose label gives a diluent volume, the reconstitution tool on the calculator site handles it and pre-fills nothing.

Travel and temperature excursions

The Egrifta labels permit excursions to 15 to 30 C for the unreconstituted vial. That is the manufacturer's tested tolerance for that product; it says nothing about a compounded vial. For any pharmacy-dispensed preparation, the pharmacy that assigned the beyond-use date is the party that can say what an excursion does to it. Ask, and if the answer is uncertain, the conservative course is the one every label implies: when in doubt, discard.

Questions people ask

Can I use the Egrifta storage rules for a compounded tesamorelin?

No. The Egrifta labels describe the stability of Theratechnologies' specific formulations (with their specific excipients, vial fill and diluent) as tested for FDA. A compounded tesamorelin is a different preparation with a beyond-use date set by the pharmacy under USP compounding standards. Follow the pharmacy label. If it lacks a beyond-use date or storage instruction, ask before using it.

What is a beyond-use date?

The date after which a compounded preparation must not be used, assigned by the compounding pharmacy based on the preparation's components, sterility risk and storage. It is the compounded-product equivalent of an expiry date, usually much shorter. The storage-life countdown on this page counts down to whatever date your pharmacy printed.

Why do Egrifta SV and Egrifta WR have different rules?

They are different formulations. SV is a 2 mg single-dose vial reconstituted with sterile water (no preservative), so the solution must be used at once. WR is an 11.6 mg vial reconstituted with bacteriostatic water (which contains benzyl alcohol as a preservative) to give a week of daily doses, so the label allows 7 days after mixing. The WR label states the two are not substitutable.

Canonical URL: https://formblendspeptides.com/guides/storage-and-handling-of-prescribed-peptide-medication. Written by the FormBlends editorial team. This page is educational and is not medical advice; see the medical disclaimer.